Paliperidone‐Induced Catatonia: Case Series and Review of Literature
Abstract
Paliperidone, a second‐generation antipsychotic commonly used to treat schizophrenia and schizoaffective disorder, has been rarely associated with inducing catatonia, a severe neuropsychiatric syndrome characterized by motor disturbances and altered mental status. We present two cases demonstrating variable onset of paliperidone‐induced catatonia: a 20‐year‐old male with acute symptoms following intramuscular loading doses and a 24‐year‐old female with a delayed presentation. Both cases highlight the clinical challenge of timely recognition, which is critical to prevent serious complications such as dehydration and respiratory failure. Assessment using the Bush‐Francis Catatonia Rating Scale (BFCRS) guided treatment with benzodiazepines and antipsychotic adjustments, resulting in significant symptom improvement. This case series underscores the need for heightened awareness of this rare adverse effect to facilitate early diagnosis and optimize outcomes in patients receiving paliperidone.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.